Assertio to Participate in the 2023 Winter Wonderland Best Ideas Conference

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

LAKE FOREST, Ill., Feb. 16, 2023 (GLOBE NEWSWIRE) — Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT), a specialty pharmaceutical company offering differentiated products to patients, today announced that Dan Peisert, CEO, and Paul Schwichtenberg, CFO, will host investor meetings Thursday, February 23, 2023 as part of the virtual Third Annual Winter Wonderland Best Ideas Investor Conference.

As part of the conference event, management will host a webcast group presentation on Wednesday, February 22, 2023 at 9:30 am Eastern Time. The webcast will be available on the Investor Relations section of the Assertio website, located at www.assertiotx.com.

For more information about scheduling a one-on-one meeting with management, please contact the conference hosts via email at angie.wright@issuerdirect.com, or Matt Kreps, Investor Relations for Assertio Holdings, at mkreps@darrowir.com.

About Assertio

Assertio is a leading commercial pharmaceutical company bringing differentiated products to patients. The Company has a robust portfolio of branded prescription products in three areas: neurology, hospital, and pain and inflammation. Assertio has grown through business development including licensing, mergers, and acquisitions. To learn more visit www.assertiotx.com.

Investor Contact:

Matt Kreps
Managing Director
Darrow Associates
Austin, TX 
M: 214-597-8200
mkreps@darrowir.com

Staff

Recent Posts

Introducing Tempus One in the EHR with Integrated Guidelines

The AI-enabled clinical assistant is available to query patient data across the EHR as well…

5 hours ago

Novartis Kisqali® reduces risk of recurrence in younger patients with early breast cancer in NATALEE subgroup analysis

33% reduction in relative risk of invasive disease observed in pre-menopausal early breast cancer (EBC)…

5 hours ago

Seer’s Proteograph Platform Enables Unprecedented 20,000-Sample Proteomics Study with Korea University to Develop AI-Driven Diagnostics for Cancers in Young Adults

First-of-its-kind study will use Seer’s next-generation workflow to identify early-onset cancer biomarkers and power deep,…

5 hours ago